The Department of Health and Human Services plans to cancel contracts and pull funding for some vaccines being developed to ...

Pfizer stock rose after the drugmaker posted adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Big Pharma admits it is discussing Trump’s plan to lower drug prices - Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer opti ...

Live Updates Live Coverage Updates appear automatically as they are published. Investors Don't Like the Taste of Yum! 9:37 am ...

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...

Pfizer ( PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the ...

President Donald Trump said his administration is prepared to increase the tariffs it plans to impose on pharmaceuticals up ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...

Pfizer (PFE) increased its 2025 profit outlook by 10 cents a share to a range of $2.90 to $3.10 a share, citing continued cost cuts, a lower tax rate and "confidence" that strength seen in the first ...

Welcome to Contract Pharma’s annual ranking of the Top 20 Pharma and Biopharma Companies, based on fiscal year 2024 ...